Evidence map›Paper›PMID 38625090›Full record

ArticleHLA2024

High-resolution KIR and HLA genotyping in three Chinese ethnic minorities reveals distinct origins.

Sudan Tao, Paul J Norman, Xuan You, Katherine M Kichula, Lina Dong, Nanying Chen, Yizhen He, Chen Chen, Wei Zhang, Faming Zhu

Open access · greenAbstract read
In one paragraph

Article in HLA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sudan TaoBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Paul J NormanDivision of Biomedical Informatics and Personalized Medicine, and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Xuan YouBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Katherine M KichulaDivision of Biomedical Informatics and Personalized Medicine, and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Lina DongBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Nanying ChenBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Yizhen HeBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Chen ChenBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.ORCID 0000-0002-7651-1216
Wei ZhangBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.
Faming ZhuBlood Center of Zhejiang Province, Key Laboratory of Blood Safety Research of Zhejiang Province, Zhejiang, Hangzhou, People's Republic of China.ORCID 0000-0002-1963-9176
Blood Center of Zhejiang Province · CNUniversity of Colorado Denver · US

Funding

Evolution and Function of Immunogenetic Diversity across the Eastern HemisphereR01AI151549 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Paul John Norman · 2022 to 2026
$3.9M
NIAID NIH HHS R01 AI151549
6 · The paper itself

Abstract

Polymorphism of killer-cell immunoglobulin-like receptors (KIRs) and their HLA class I ligands impacts the effector activity of cytotoxic NK cell and T cell subsets. Therefore, understanding the extent and implications of KIR and HLA class I genetic polymorphism across various populations is important for immunological and medical research. In this study, we conducted a high-resolution investigation of KIR and HLA class I diversity in three distinct Chinese ethnic minority populations. We studied the She, Yugur, and Tajik, and compared them with the Zhejiang Han population (Zhe), which represents the majority Southern Han ethnicity. Our findings revealed that the Tajik population exhibited the most diverse KIR copy number, allele, and haplotype diversity among the four populations. This diversity aligns with their proposed ancestral origin, closely resembling that of Iranian populations, with a relatively higher presence of KIR-B genes, alleles, and haplotypes compared with the other Chinese populations. The Yugur population displayed KIR distributions similar to those of the Tibetans and Southeast Asians, whereas the She population resembled the Zhe and other East Asians, as confirmed by genetic distance analysis of KIR. Additionally, we identified 12.9% of individuals across the three minority populations as having KIR haplotypes characterized by specific gene block insertions or deletions. Genetic analysis based on HLA alleles yielded consistent results, even though there were extensive variations in HLA alleles. The observed variations in KIR interactions, such as higher numbers of 2DL1-C2 interactions in Tajik and Yugur populations and of 2DL3-C1 interactions in the She population, are likely shaped by demographic and evolutionary mechanisms specific to their local environments. Overall, our findings offer valuable insights into the distribution of KIR and HLA diversity among three distinct Chinese ethnic minority populations, which can inform future clinical and population studies.

Indexed as

East Asian PeopleEthnic and Racial MinoritiesMinority GroupsReceptors, KIRAllelesChinaEthnicityGenotypeHumansReceptors, KIRChineseHLAKIRSheTajikYugur

Identifiers

PMID38625090
PMCPMC11027949
OpenAlexW4394853821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.